EZ Cap™ Mouse CD86 mRNA (m1Ψ, HA tag)

CD86 is an important immunomodulatory molecule that belongs to the B7 family of transmembrane proteins and is mainly expressed on the surface of antigen-presenting cells such as dendritic cells, macrophages and B cells. It plays a key role in the immune system, regulating T cell activation and immune response by binding to CD28 and CTLA-4 receptors on the surface of T cells. Binding of CD86 to CD28 promotes the activation and proliferation of T cells, while binding to CTLA-4 inhibits T cell activity, thereby maintaining the balance of the immune system. CD86 is critical in a variety of immune responses, including infections, tumor immunity, and autoimmune diseases. The study suggests that modulating CD86 activity may provide new strategies for treating a variety of immune-related diseases.

EZ Cap™ Mouse CD86 mRNA (m1Ψ, HA tag) is provided at a concentration of ~1 mg/ml with Cap1 structure. It expresses Mouse CD86 cytokine with HA label, which is convenient for the subsequent detection of protein expression. There are currently two ways to cap mRNA: One is co-transcription method, by adding Cap analogues into the transcription process. The other is enzymatic Capping. After transcription, Cap0 capping is performed by Vaccinia virus Capping Enzyme (VCE), GTP and S-adenosylmethionine (SAM). The Cap0 is then generated into the Cap1 through 2´-O-Methyltransferase and SAM. Cap1 Capping can also be performed by adding VCE, 2´-O-Methyltransferase, GTP and SAM in a one-step process. Cap 1 structure is more ideal for mammalian systems and possess higher transcription efficiency than Cap 0 structure. The addition of N1-Methylpseudo-UTP(m1Ψ) and poly(A) tail suppress RNA-mediated innate immune activation and increase the stability and lifetime of the mRNA in vitro and in vivo. Poly(A) tail also plays an important role in enhancing the efficiency of translation initiation.